Tags: Affymax | fda | anemia | amgen | J&J

Affymax Wins FDA Panel Backing on Anemia Drug

Wednesday, 07 Dec 2011 05:26 PM

Affymax Inc. won a U.S. panel’s backing for an experimental anemia medicine that would compete with treatments marketed by Amgen Inc. and Johnson & Johnson for patients with chronic kidney disease.

The benefits of the drug, known as peginesatide, outweigh potential heart risks, outside advisers to the Food and Drug Administration said today in a 15-1 vote in Silver Spring, Maryland. The FDA isn’t required to follow the advisory panels’ recommendations.

Peginesatide would be Palo Alto, California-based Affymax’s first product if it gains FDA approval.

© Copyright 2017 Bloomberg News. All rights reserved.

   
1Like our page
2Share
Companies
Affymax Inc. won a U.S. panel s backing for an experimental anemia medicine that would compete with treatments marketed by Amgen Inc. and Johnson Johnson for patients with chronic kidney disease.The benefits of the drug, known as peginesatide, outweigh potential heart...
Affymax,fda,anemia,amgen,J&J
85
2011-26-07
Wednesday, 07 Dec 2011 05:26 PM
Newsmax Inc.
 

Newsmax, Moneynews, Newsmax Health, and Independent. American. are registered trademarks of Newsmax Media, Inc. Newsmax TV, and Newsmax World are trademarks of Newsmax Media, Inc.

NEWSMAX.COM
MONEYNEWS.COM
© Newsmax Media, Inc.
All Rights Reserved